ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1979

Participant Engagement and Adherence in an ArthritisPower Real-World Study to Capture Smartwatch and Patient-Reported Outcome Data Among Rheumatoid Arthritis Patients

William Nowell1, Jeffrey R Curtis2, Hong Zhao3, Fenglong Xie3, Laura Stradford4, David Curtis5, Kelly Gavigan4, Jessica Boles4, Justin Owensby3, Cassie Clinton2, Ilya Lipkovich6, Shilpa Venkatachalam7, Sandra Nolot6 and Virginia Haynes6, 1Global Healthy Living Foundation, New York City, NY, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Global Healthy Living Foundation, Upper Nyack, NY, 5Global Healthy Living Foundation, New York City, 6Eli Lilly & Company, Indianapolis, IN, 7Global Healthy Living Foundation, Upper Nyack

Meeting: ACR Convergence 2020

Keywords: Measurement, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Patient Outcomes, Preferences, & Attitudes II: Engagement, Perceptions, & Quality of Life (1978–1982)

Session Type: Abstract Session

Session Time: 11:00AM-11:50AM

Background/Purpose: Characterization of how different types of patient-generated data reflect patients’ experience is needed to guide integration of electronically collected patient-reported outcome (ePRO) measures and passive biometrics into real-word evidence (RWE) platforms. Our objective was to characterize engagement, protocol adherence, and data completeness in an ongoing study in rheumatoid arthritis (RA) participants (pts) enrolled in the Digital Tracking of Arthritis Longitudinally (DIGITAL) study, an ancillary study of the ArthritisPower® registry.

Methods: Pts were invited to join the app-based study which included a 2-week (14-day) Lead-In and 12-week (84-day) Main Study Period. Study-specific customization of the ArthritisPower mobile application collected ePROs. For at least 10 days of the Lead-In period, pts were required to electronically complete: a) two daily single-item Pain and Fatigue numeric rating scales and b) longer weekly sets of ePROs. Successful completers of the Lead-In were mailed a smartwatch (Fitbit® Versa™) and study materials. Main Study Period included automated and manual prompts to complete ePROs, wear the smartwatch and regularly sync it. Study coordinators monitored pt data and contacted pts via email, text and/or phone to resolve adherence issues per a priori rules triggering pt contact due to consecutive spans of missing data. Adherence to data collection during the Main Study was defined as providing requested data > 70% of 84 days (daily ePRO, smartwatch data), or ≥ 9 of 12 weeks.

Results: As of 4/2020, and referent to the 470 pts expressing initial interest, 278 (59.1%) completed the Lead-In and qualified for the Main Study. Of the 278 pts enrolled, 91.7% female, mean (SD) age 50.2 (11.1), 9.4 (10.1) years since RA diagnosis (Table 1). Those qualifying for the Main Study were more likely to be currently employed (55.4% vs. 39.6%, p< 0.01) and on biologic monotherapy (63.3% vs. 49.5%, p< 0.01). Over the 84-day Main Study period, the proportion of pts meeting the definition of adherence to protocol-specified data collection was lowest (57%) for daily ePRO data capture, highest for weekly ePRO data (87%), and intermediate (82%) for smartwatch data. A total of 147 (53%) of pts met composite adherence (Figure), while 27/278 met neither smartwatch/PRO adherence, 80/278 met smartwatch adherence but not PRO adherence, and 24/278 did not meet smartwatch adherence but met PRO adherence. Pts experiencing high levels of pain and low levels of physical function at Lead-In were more likely to complete ePROs but not adhere to smartwatch use when they advanced to the Main Study period (Table 2).

Conclusion: Compared to other digital health RA studies, a short lead-in period appears useful to identify pts likely to engage in a longitudinal digital health study collecting data on a mobile app and was associated with subsequent pt adherence, and this adherence may vary by data collection platform. RWE studies involving passive data collection in RA require pt-centric implementation and design to minimize pt burden, promote longitudinal engagement and maximize adherence.

*Statistical significance between groups of pts who qualified and did not qualify for Main Study, p < 0.05; t tests were performed for continuous variables and chi square tests for categorical variables; p values are nominal in nature and should be interpreted in an exploratory manner ƚ DMARDs = disease modifying antirheumatic drugs csDMARDs = conventional synthetic DMARDs (e.g. methotrexate, sulfasalazine) bDMARDs = biologics or biologic DMARDs (e.g. TNFi, IL-6, IL-7) tsDMARDs = targeted synthetic DMARDs (e.g. JAKi) None of the above = on NSAIDs or corticosteroids, but no DMARD or cs/b/tsDMARD

*Statistical significance between groups of pts who met and did not meet composite adherence in Main Study, p < 0.05; t tests were performed for continuous variables and chi square tests for categorical variables; p values are nominal in nature and should be interpreted in an exploratory manner ƚ DMARDs = disease modifying antirheumatic drugs csDMARDs = conventional synthetic DMARDs (e.g. methotrexate, sulfasalazine) bDMARDs = biologics or biologic DMARDs (e.g. TNFi, IL-6, IL-7) tsDMARDs = targeted synthetic DMARDs (e.g. JAKi)


Disclosure: W. Nowell, None; J. Curtis, AbbVie, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Janssen, 2, 5, Lilly, 2, 5, Myriad, 2, 5, Pfizer, 2, 5, Regeneron, 2, 5, Roche, 2, 5, UCB, 2, 5, Gilead Sciences, Inc., 5, Sanofi, 5; H. Zhao, None; F. Xie, None; L. Stradford, None; D. Curtis, None; K. Gavigan, None; J. Boles, None; J. Owensby, None; C. Clinton, None; I. Lipkovich, Eli Lilly and Company, 1, 3; S. Venkatachalam, None; S. Nolot, Eli Lilly and Company, 1, 3; V. Haynes, Eli Lilly and Company, 1, 3.

To cite this abstract in AMA style:

Nowell W, Curtis J, Zhao H, Xie F, Stradford L, Curtis D, Gavigan K, Boles J, Owensby J, Clinton C, Lipkovich I, Venkatachalam S, Nolot S, Haynes V. Participant Engagement and Adherence in an ArthritisPower Real-World Study to Capture Smartwatch and Patient-Reported Outcome Data Among Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/participant-engagement-and-adherence-in-an-arthritispower-real-world-study-to-capture-smartwatch-and-patient-reported-outcome-data-among-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/participant-engagement-and-adherence-in-an-arthritispower-real-world-study-to-capture-smartwatch-and-patient-reported-outcome-data-among-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology